YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor and is used to treat several different types of ophthalmology conditions

Biocon Biologics’ settlement and license agreement with Regeneron clears the way to commercialise Yesafili (aflibercept-jbvf), an interchangeable biosimilar aflibercept, in the US. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions and is a biosimilar of its reference product EYLEA (aflibercept).

Biocon Biologics and Regeneron executed the settlement agreement to dismiss the pending appeal at the United States Court of Appeals for the Federal Circuit (USCAFC) of patent US11084865 (‘865 patent) and the pending litigation at the US District Court for the Northern District of West Virginia, Clarksburg Division.

The agreement enables the company to launch in the US in the second half of the calendar year 2026 or earlier in certain circumstances. The terms of the settlement are confidential.

Shreehas Tambe, CEO and MD, Biocon Biologics, said, “The settlement clears the path for Biocon Biologics to be among the first to bring a reliable, high-quality aflibercept biosimilar to patients and healthcare providers in the US. As the first-to-file interchangeable biosimilar to Eylea, YESAFILI affirms our scientific strength and marks our strategic entry into Ophthalmology, expanding our footprint in the US and advancing our mission to increase access to life-changing treatments.”

Previously, the US Food and Drug Administration approved Yesafili (aflibercept-jbvf), an interchangeable biosimilar aflibercept in May 2024. Additionally, Biocon Biologics secured a settlement agreement in Canada with Bayer and Regeneron Pharmaceuticals, for the launch of YESAFILI no later than July 1, 2025.

YESAFILI is intended for the treatment of neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME) and visual impairment due to myopic choroidal neovascularisation (myopic CNV). It is highly similar to the reference product Eylea (aflibercept).